← Back

Wire · opportunities

A new strategy for secondary stroke prevention gets boost from FDA approval

Published

11 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at managedhealthcareexecutive.com →

◆ Verified

Fusion42 · 11 November 2026 · Fusion42 review

The FDA approved Sunharbo (asundexian), a first-in-class Factor XI inhibitor, to reduce the risk of secondary ischemic stroke by 26% without increasing major bleeding risks. The drug is intended for adults with mild-to-moderate noncardioembolic stroke or high-risk transient ischemic attack (TIA) and is to be used alongside antiplatelet therapy.

This Wire brief sits within Fusion42's coverage of Medtech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

Your stroke treatment options just expanded with a drug that lowers risk without raising bleeding. If you work in Medtech or healthcare, buyers and patients will expect safer secondary stroke therapies this year.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Medtechstroke-preventionfda-approvalanticoagulantsfactor-xi-inhibitorbayer